Prospective Episealer® Talus study 50% recruited

Episurf Medical (Nasdaq: EPIS B) today announces that 50% of the patients have been recruited to a prospective study on the Episealer Talus® implant, lead by Prof. Zaffagnini, from the Rizzoli Orthopaedic Institute in Bologna, Italy, supported by Dr Massimiliano Mosca.

The study will follow 15 patients who received an Episealer Talus® implant as treatment for osteochondral defects in their ankle joint. Episealer® Talus is Episurf Medical’s CE marked implant technology, intended for the treatment of osteochondral ankle lesions. 

“This is an interesting technology, and we are happy to be able to help our patients with this individualized technology”, says Prof. Zaffagnini.

“We are pleased to see the efficient patient recruitment in this very important initiative, and it is an honour to work with the prestigious Rizzoli Orthopaedic Institute in Bologna,” says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags: